5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A comprehensive review of methimazole (Tapazole) adverse event incidence rates from clinical trials, FDA labeling, FAERS data, and post-market literature, with specific percentages, named studies, and clinical guidance.
A guide to methimazole (Tapazole) side effects, with special focus on potentially permanent adverse events including agranulocytosis, aplastic anemia, liver damage, and vasculitis, backed by FDA labeling, FAERS data, and primary trial evidence.
A guide to the rare but serious adverse events linked to methimazole (Tapazole), including agranulocytosis, hepatotoxicity, vasculitis, and teratogenicity, with trial data, FAERS reports, and FDA label citations.
A clinical breakdown of methimazole adverse events by frequency, severity, and patient phenotype, covering agranulocytosis risk, hepatotoxicity, teratogenicity, and dose-dependent effects with primary-source citations.
A guide to methimazole (Tapazole) withdrawal and discontinuation syndrome, covering rebound hyperthyroidism, agranulocytosis risk, tapering strategies, and post-market safety data from FAERS and clinical trials.